Point72 Asset Management
KRTX

Point72 Asset Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Point72 Asset Management’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-64,630
Closed -$20.5M – 2737
2023
Q4 		$20.5M Sell
64,630
-283,170
-81% -$55M 0.05% 419
2023
Q3 		$58.8M Buy
347,800
+301,860
+657% +$56.8M 0.17% 137
2023
Q2 		$9.96M Sell
45,940
-517,558
-92% -$111M 0.03% 586
2023
Q1 		$102M Buy
563,498
+486,506
+632% +$93M 0.32% 65
2022
Q4 		$15.1M Sell
76,992
-191,108
-71% -$41M 0.05% 415
2022
Q3 		$60.3M Buy
+268,100
New +$54.3M 0.24% 105
2022
Q2 		– Sell
-191,800
Closed -$24.3M – 1706
2022
Q1 		$24.3M Buy
191,800
+98,703
+106% +$11.1M 0.1% 283
2021
Q4 		$12.2M Buy
+93,097
New +$12M 0.05% 458
2019
Q4 		– Sell
-37,737
Closed -$616K – 1319
2019
Q3 		$616K Buy
+37,737
New +$733K ﹤0.01% 757

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Point72 Asset Management's KRTX Position: Q1 2024 in Review

Point72 Asset Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 64,630 shares — an estimated $20.5M sold.

Point72 Asset Management first reported a position in KRTX in Q3 2019 and held it in 9 quarters. The position peaked at $102M in Q1 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Point72 Asset Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Point72 Asset Management sold 64,630 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $20.5M.
  • Point72 Asset Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2019 and held it in 9 quarters.
  • Point72 Asset Management's Karuna Therapeutics, Inc. Common Stock position peaked at $102M in Q1 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Point72 Asset Management's 13F filing for Q1 2024, filed 15 May 2024.